Clinical trials: Vorinostat
Malignant Glioma, Recurrent Glioblastoma
Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
The goal of this Phase I portion of this clinical research study is to find the highest tolerable dose of bevacizumab with or without vorinostat, that can be given to patients with malignant gliomas.
- Trial name
- NCT01266031
- Testing
- vorinostat, bevacizumab
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or idarubicin and cytarabine with or without vorinostat to see how well they work in treating younger patients with previously untreated acute…
- Trial name
- NCT01802333
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cytarabine, Daunorubicin Hydrochloride
- Where
- 447 sites in United States, Canada
- Volunteers
- 754 people
- Sponsor
- National Cancer Institute (NCI)
AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
This partially randomized phase I/II trial studies the side effects and the best dose of vorinostat when given together with combination chemotherapy and rituximab to see how well it works compared to combination chemotherapy…
- Conditions
- AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage I Grade 3 Follicular Lymphoma
- Trial name
- NCT01193842
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
- Where
- 35 sites in United States
- Volunteers
- 107 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
The goal of this clinical research study is to find out how well the drug Zolinza (vorinostat) works in combination with the drug combination called CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) to treat…
- Trial name
- NCT00787527
- Testing
- Zolinza (vorinostat), Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
This phase I/II trial studies the side effects of pembrolizumab and vorinostat in treating patients with squamous cell head and neck cancer or salivary gland cancer that has come back, has spread to other places in the body…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Salivary Gland Carcinoma
- Trial name
- NCT02538510
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Advanced Cancer Relapsed, Advanced Cancer Refractory
A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)
A 2-period, crossover study to assess the effects of MK0683 (vorinostat) on the QTc interval in patients with relapsed or refractory advanced cancer.
- Trial name
- NCT00632931
- Testing
- vorinostat
- Volunteers
- 25 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non Small Cell Lung
Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy of vorinostat and bortezomib in the third line treatment of advanced NSCLC, as well as to assess toxicity (including neuropathy) and tolerability of this regimen.
- Trial name
- NCT00798720
- Testing
- vorinostat, bortezomib
- Volunteers
- 18 people
- Sponsor
- University of Wisconsin, Madison
Tumors
A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)
This is a clinical study to evaluate the safety and pharmacokinetics of an overseas determined maximum tolerated dose (MTD) of MK-0683 (vorinostat) in a Japanese patient population with solid tumors.
- Trial name
- NCT00373490
- Testing
- Vorinostat
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer
Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)
This is a clinical trial to determine the safety and tolerability of MK0683 in combination with gemcitabine and cisplatin and/or carboplatin.
- Trial name
- NCT00423449
- Testing
- vorinostat, Gemcitabine, Platinum-based agent
- Volunteers
- 61 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
The purposes of this study are: To determine the maximum tolerated dose (MTD) for the combination of oral vorinostat and bortezomib in participants with advanced multiple myeloma To assess the safety and tolerability of this…
- Trial name
- NCT00111813
- Testing
- vorinostat, bortezomib
- Volunteers
- 34 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer, Neoplasm Metastasis
GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
This research is being done to find out how safe and how well the combination of lapatinib and vorinostat works against advanced cancers.
- Trial name
- NCT01118975
- Testing
- Vorinostat, Lapatinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Maryland, Baltimore
Brain Cancer, Glioblastoma Multiforme
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
Phase I Objectives: -To determine the maximum tolerated dose (MTD) of vorinostat + erlotinib versus vorinostat + erlotinib + temozolomide in adult patients with recurrent glioblastoma multiforme (GBM) and anaplastic gliomas.
- Trial name
- NCT01110876
- Testing
- Vorinostat, Erlotinib, Temozolomide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Stage IIIB or IV Non-Small Cell Lung Cancer
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
This Phase III clinical trial which incorporates an initial Phase II component will determine the survival of advanced Non-small cell lung cancer patients when treated with MK0683 and paclitaxel plus carboplatin
- Trial name
- NCT00473889
- Testing
- vorinostat, Comparator: paclitaxel, Comparator: carboplatin
- Volunteers
- 253 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Myeloid Leukemia
Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype
This research is being done because treatment options are very limited and usually unsuccessful for Acute Myeloid Leukemia (AML) in older individuals, or younger people with disease that has relapsed and/or proven resistant to…
- Trial name
- NCT01534260
- Testing
- sorafenib, vorinostat and bortezomib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Hamid Sayar
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
The goal of this clinical research study is to find the highest safe dose of vorinostat that can be given in combination with idarubicin and ara-C for the treatment of AML and high-risk MDS.
- Trial name
- NCT00656617
- Testing
- Idarubicin, Cytarabine, Vorinostat
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
This is a pilot study using decitabine and vorinostat before and during chemotherapy with vincristine, dexamethasone, mitoxantrone, and peg-asparaginase in pediatric patients with acute lymphoblastic leukemia (ALL).
- Conditions
- Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia, Precursor T-Cell Lymphoblastic Leukemia
- Trial name
- NCT01483690
- Testing
- Decitabine, Vorinostat, Vincristine
- Where
- 28 sites in United States, Australia
- Volunteers
- 23 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with rituximab, ifosfamide, carboplatin, and etoposide and to see how well they work in treating patients with relapsed or…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Contiguous Stage II Mantle Cell Lymphoma
- Trial name
- NCT00601718
- Testing
- vorinostat, rituximab, ifosfamide
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Washington
HIV
Research In Viral Eradication of HIV Reservoirs
This study will be a two-arm prospective 1:1 randomised controlled trial comparing: Arm A: cART preferably including raltegravir (combination ART cART - control) Arm B: cART preferably including raltegravir (cART) plus…
- Trial name
- RIVER (NCT02336074)
- Testing
- Combination Antiretroviral Therapy (cART), Raltegravir, Vorinostat
- Where
- 6 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Imperial College London
Lymphoma, Small Intestine Cancer
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth, and may stimulate the immune system to stop cancer cells from growing.
- Trial name
- NCT00561418
- Testing
- vorinostat, Correlative studies
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
HIV-1 Infection
Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons
Adult participants (18-64 years old) with HIV-1 Infection on ART with a CD4 T cell count ≥ 350 cells/mm3 and viral suppression for ≥ 24 months will be enrolled on this study.
- Trial name
- NCT03803605
- Testing
- VRC07-523LS, Vorinostat (VOR)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of North Carolina, Chapel Hill